Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: treat-to-target

2015 ACR Workforce Study Report Offers Rheumatologists Chance to Improve Patient Care, Financial Outlook

Timothy Harrington, MD  |  December 13, 2016

I read the 2015 ACR Workforce Study Report with great interest as one who served on the 2005 Manpower Taskforce.1,2 I found it disappointing that the deficit in rheumatologist FTEs that we predicted a decade ago has become a fact. Of even greater concern, the strategies we proposed to address this problem have not been…

Filed under:Practice SupportQuality Assurance/ImprovementWorkforce Tagged with:Association of Rheumatology Professionals (ARP)financespatient carepatient satisfactionPractice Managementrheumatologistrheumatologystudy

FDA Update on Rituximab & Etanercept; Plus New ACP Gout Guideline

Michele B. Kaufman, PharmD, BCGP  |  November 30, 2016

The FDA is considering an application for subcutaneous rituximab and has approved an application for etanercept to treat pediatric patients with plaque psoriasis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesGout and Crystalline ArthritisPediatric Conditions Tagged with:American College of PhysiciansetanerceptFDAFood and Drug AdministrationGoutguidelinePediatricplaque psoriasisrituximab

Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies

Michele B. Kaufman, PharmD, BCGP  |  August 11, 2016

Cross Reactions A recent study published online in March in the Annals of the Rheumatic Diseases investigated if the infliximab biosimilar (CT-P13, infliximab-dyyb), which is marketed in Europe as Inflectra and Remsima, can be safely and effectively substituted for infliximab (Remicade).1 Infliximab and its biosimilar are manufactured via the same process. Researchers set out to…

Filed under:Biologics/DMARDsConditionsDrug Updates Tagged with:AntibodiesBiologicsDisease-modifying antirheumatic drugs (DMARDs)drugFDAinfliximabRheumatoid arthritisrheumatologySafetytherapyTreatmentupdate

Methotrexate with Step-Down Glucocorticoid Remission Induction Works in Early RA

Reuters Staff  |  August 1, 2016

NEW YORK (Reuters Health)—Methotrexate with step-down glucocorticoid remission induction (COBRA Slim) is an effective, safe and feasible initial treatment strategy for patients with early rheumatoid arthritis (RA), researchers from Belgium report. Patients with early RA should be treated rapidly, intensively and to target, according to current guidelines, they note in a paper online July 18…

Filed under:Drug Updates Tagged with:glucocorticoidMethotrexateRemissionRheumatoid Arthritis (RA)

workforce

Addressing the Rheumatology Workforce Shortage

Timothy Harrington, MD, Erin Arnold, MD, William Arnold, MD, David Sikes, MD, Gary Crump, MD, James Bower, MPA, & Drew Johnson, MS, MBA  |  May 13, 2016

In 2008, the American College of Rheumatology Workforce Study Advisory Group published a comprehensive rheumatology workforce analysis.1 It concluded: Based on assessment of supply and demand under current scenarios, the demand for rheumatologists is expected to exceed supply in the coming decades. Strategies for the profession to adapt to this changing health care landscape include…

Filed under:Practice SupportWorkforce Tagged with:Practice Managementrheumatologistsrheumatologyshortage

Tips for Setting Treatment Goals with the Patient

Karen Appold  |  May 13, 2016

When working with a newly diagnosed patient to determine a treatment plan, ensure the patient has a good understanding of the diagnosis, the options available and what the options entail. “It is important to help patients understand that there are choices, and that their decisions should be based on what matters to them,” says Susan…

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:patient carerheumatologistrheumatologytreatment goals

2015 ACR/ARHP Annual Meeting: Immune Mediators Can Impact Inflammatory Response

Susan Bernstein  |  March 15, 2016

SAN FRANCISCO—Inflammation can be either acute or chronic, and it’s the inflammatory responses that don’t shut down normally, or resolve, that cause tissue damage in rheumatic disease. “Resolution bridges the gap between acute inflammation and adaptive immunity,” said Derek W. Gilroy, PhD, head of the Centre for Clinical Pharmacology and Professor of Immunology at University…

Filed under:ConditionsMeeting ReportsOther Rheumatic ConditionsResearch Rheum Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)fatty acidsinflammationlipidsResearchRheumatic Diseasetissue damage

Patient-Centered Care Model for RA Flares Could Improve Self-Management of Symptoms

Mary Beth Nierengarten  |  December 16, 2015

A recent trend to incorporate patient-reported outcomes (PROs) in clinical research, and ultimately clinical practice, is a response to the need to better measure and treat what patients truly care about, and adapt to the changing healthcare environment, which increasingly includes patient satisfaction as a key metric for overall quality of care, a metric tied…

Filed under:ConditionsPractice SupportRheumatoid Arthritis Tagged with:patient carepatient-centered carePractice ManagementRARheumatoid arthritisself-managementsymptomsTreatment

Dr. Michael Weinblatt Discusses Current & Future RA Therapies

Richard Quinn  |  December 11, 2015

According to former ACR President Michael Weinblatt, MD, the future of drug therapies for patients with RA rests in the careful and intelligent prescription of current medications and treatment combinations, as well as better patient access through lower costs…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:BiologicsBiologics & Biosimilarscombination therapydrug therapyMethotrexateRheumatoid Arthritis (RA)

2015 ACR Guideline for the Treatment of Rheumatoid Arthritis

Arthritis & Rheumatology  |  November 30, 2015

“Treat to target regardless of disease activity level” tops the list of recommendations for both early and established RA in the 2015 Guideline for the Treatment of Rheumatoid Arthritis. The guideline addresses six major topics, including DMARDs, glucocorticoids and biologics, and includes 74 recommendations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients together…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:ACR/AHRP Annual MeetingArthritis & RheumatologyBiologicsDisease-modifying antirheumatic drugs (DMARDs)Research

  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences